NCT01569828View on ClinicalTrials.gov

Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
PharmacokineticsRenal ImpairedHealthy Volunteer
Interventions
DRUG

LCZ696A

DRUG

LCZ696A

once daily administration of 400 mg LCZ696 for 5 days

Trial Locations (3)

41460

Novartis Investigative Site, Neuss

117292

Novartis Investigative Site, Moscow

Unknown

Novartis Investigative Site, Belgrade

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY